Herpes Simplex Virus Testing Kits Market Report 2026: Analyst-Verified Data & Forecast

Herpes Simplex Virus Testing Kits by Application (Diagnostic Centers, Hospitals, Home Use), by Types (Antibody/Antigen Based Kit, Viral Culture Test Kits, Nucleic Acid Amplification-based Kits), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Herpes Simplex Virus Testing Kits Market Overview

Herpes Simplex Virus (HSV) testing kits encompass molecular, antigen and antibody assays used to detect HSV-1 and HSV-2 infection. With an estimated 3.7 billion people under-50 already infected with HSV-1 and 500 million with genital HSV-2, accurate, rapid self-collection tools are becoming a frontline defence against onward transmission. The global Herpes Simplex Virus Testing Kits market size is projected to reach USD 1.94 billion in 2025, advancing at a 7.1% CAGR through 2033, underpinned by widening STI-screening guidelines, normalization of at-home sample collection, and reimbursement tailwinds across North America and the EU5. Growth outlook is further lifted by multiplex PCR panels that consolidate HSV with CT/NG/Trichomonas, rising female health literacy, and the entry of digital-health platforms that convert one-off test sales into subscription-based, repeat-order models.

Loading chart…

Technology shifts toward isothermal amplification and smartphone-read lateral-flow devices are slashing time-to-result to <20 minutes, while CLIA-waived status is moving testing from labs to pharmacies; competitive intensity is rising as diagnostics majors bundle HSV modules into comprehensive sexual-health menu. Regulation remains the double-edged sword: FDA’s proposed reclassification of certain rapid HSV serology tests to Class III will raise compliance costs, but simultaneously weed out low-quality entrants, consolidating share among evidence-rich leaders. North America will continue to command the largest slice of the market forecast (≈41% share in 2025), yet Asia-Pacific is the fastest-expanding region—driven by India’s National STI Program scale-up, China’s Healthy China 2030 initiative, and widening e-pharmacy channels that discreetly deliver self-tests to tier-2 cities.

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; ADI/American Diagnostica; Agilent Technologies; Chrono-Log; Corgenix; Decode Genetics; Diadexus; Diagnocure; Diagnostica Stago/Trinity Biotech; Diamedix; International Technidyne/Nexus DX; Kreatech/Leica; Polymedco; Qiagen; Roche; SDIX; Sequenom; Siemens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Global incidence of genital herpes—estimated at 490 million people aged 15–49 (WHO, 2023)—is accelerating demand for confirmatory testing, pushing the Herpes Simplex Virus Testing Kits market toward a projected 6.8% CAGR and expanding Herpes Simplex Virus Testing Kits market size to USD 1.4 billion by 2030.

Adoption of high-throughput isothermal NAAT platforms (e.g., LAMP and RPA) is collapsing lab turnaround to <30 min while cutting reagent consumption 40%, making routine HSV screening in OB-GYN and urgent-care workflows economically viable.

Restraints

CMS and most EU payers reimburse multiplex STI panels but still deny separate HSV codes; average out-of-pocket cost of USD 110–140 deters asymptomatic patients and caps utilization well below volume forecasts embedded in current growth forecast models.

Single-use lyophilized reagents and cold-chain logistics for glycoprotein G–based ELISA kits raise landed costs 15–20%, compressing gross margins for distributors serving price-sensitive public-health tenders in Tier-3 regions.

Opportunities

Dual-target HSV-1/HSV-2 CRISPR-Cas12 assays integrated into smartphone-read lateral-flow strips (under CLIA-waiver review) open a USD 280 million at-home testing niche with 3× pricing power versus lab-based kits.

Bundling HSV screening with prenatal TORCH panels for private maternity clinics across MEA and ASEAN, where birth rates exceed 19 per 1,000, can add 8–10 incremental tests per pregnancy and lift account penetration 25–30% within two contract cycles.

Challenges

High seroprevalence (>70%) but low symptom recognition fuels false positives in low-prevalence cohorts, exposing manufacturers to liability claims and impending FDA tightening of clinical specificity thresholds to ≥98%.

Consolidation of reference labs (Quest, LabCorp, Synlab) squeezes supplier negotiation leverage, compressing average selling prices 5–7% YoY and forcing kit makers to absorb raw-material inflation or risk shelf-space delisting.

Market Segmentation

by asking asking when percentage

Herpes Simplex Virus Testing Kits Segmentation Breakdown8 items

Application

Diagnostic Centers

Hospitals

Home Use

Types

Antibody/Antigen Based Kit

Viral Culture Test Kits

Nucleic Acid Amplification-based Kits

Regional Insights

Loading chart…

North America dominates the global Herpes Simplex Virus Testing Kits market growth, driven by universal insurance coverage for STI screening, a mature CLIA-waived retail network, and aggressive CDC campaigns that normalize molecular testing. The region’s 2024-2029 regional forecast is underpinned by sustained capitated payments and rapid adoption of AI-guided result triage.

Asia Pacific is the fastest-growing region, expanding at a double-digit CAGR as India and Vietnam liberalize import licensing and Japan reimburses dual HSV-1/2 assays under its NHI bundle. Rising antenatal screening, 5G-enabled tele-lab platforms, and private-equity inflows into tier-2 cities are accelerating Herpes Simplex Virus Testing Kits market growth.

Europe leverages CE-IVDR harmonization and cross-border e-prescriptions to maintain the second-largest share; centralized procurement via the EU Health Union and HPV-to-HSV multiplex tenders in France and Spain create a resilient regional forecast while aging demographics elevate recurrent testing.

Latin America is transitioning from public-sector syndromic testing to self-collected kits, aided by PAHO bulk purchasing, Brazil’s Farmácia Popular subsidies, and growing millennial health awareness; however, currency volatility tempers the Herpes Simplex Virus Testing Kits market growth pace.

Middle East & Africa is supply-chain constrained yet primed for donor-led PPPs, with Saudi Vision 2030 mandating premarital screening and South Africa’s NHLS modernizing cold-chain infrastructure to expand access to Herpes Simplex Virus Testing Kits.

Competitive Landscape

The Herpes Simplex Virus Testing Kits competitive landscape is moderately consolidated, with a handful of transnational diagnostics majors—Roche, Abbott, Qiagen, and Siemens—controlling the bulk of CE- and FDA-cleared molecular assays, while a fragmented long tail of regional labs and specialty houses supplies lower-cost ELISA or immunofluorescence formats. Competitive order is shaped less by outright price leadership than by breadth of regulatory approvals, menu integration into existing PCR or immunoassay platforms, and secure hospital-lab distribution contracts; shelf-life stability, batch-to-batch reproducibility, and reimbursement coding support act as secondary levers that determine repeat purchasing.

Incumbents defend share through serial incremental assay refreshes, acquisition of complementary molecular targets, and co-development deals with PCR-instrument OEMs to lock in pull-through reagent sales; mid-tier specialists counter by localising production, offering flexible kit sizes, and positioning HSV-1/2 combined or HSV/CMV multiplex panels to raise clinician throughput. Margins remain under pressure as reference labs consolidate purchasing, reference pricing for molecular tests trends downward, and serology-based products risk commoditisation; compliance costs for IVDR and US FDA 510(k) post-market surveillance are rising, while supply-chain vulnerability to critical enzymes prolongs order lead times and tempers aggressive volume discounting.

Abbott: platform integration and menu densification drive pull-through

Qiagen: OEM supply alliances and open-system PCR consumables

Roche: premium pricing anchored by integrated sample-to-result workflows

Siemens: regional expansion via distributor partnerships in LATAM and APAC

Corgenix: local manufacturing to cut lead times and landed cost

Diadexus: focused R&D pipeline for multiplex HSV/VZV assays

Key Herpes Simplex Virus Testing Kits Companies18 items

Abbott

ADI/American Diagnostica

Agilent Technologies

Chrono-Log

Corgenix

Decode Genetics

Diadexus

Diagnocure

Diagnostica Stago/Trinity Biotech

Diamedix

International Technidyne/Nexus DX

Kreatech/Leica

Polymedco

Qiagen

Roche

SDIX

Sequenom

Siemens

Market Ecosystem

The Herpes Simplex Virus Testing Kits ecosystem spans upstream reagent and component suppliers, midstream kit manufacturers and platform integrators, and downstream clinical laboratories, point-of-care sites, and public-health programs. Value is created through iterative assay optimization, regulatory validation, and channel specialization that aligns test performance with diagnostic workflows; margin is captured where proprietary chemistries, automated readers, or data management tools create switching costs for end users.

Raw material suppliers — produce primers, probes, antigens, and nitrocellulose membranes under ISO 13485 traceability.

Assay developers — integrate reagents into PCR, isothermal, or lateral-flow formats and generate analytical validation data.

Platform technology providers — supply thermal cyclers, fluorescence detectors, and benchtop readers with embedded software.

Contract manufacturers — perform bulk lyophilization, blister packaging, and kit assembly under GMP controls.

Regulatory consultants — prepare 510(k) or CE-IVDR dossiers and manage post-market surveillance documentation.

Distributors — stock temperature-controlled inventory, offer local language support, and handle customs clearance.

End users — hospital labs, sexual-health clinics, and retail pharmacies that process specimens and report results.

Adoption velocity is gated by reference-lab partnerships that validate new kit lots against predicate assays, creating a control point for manufacturers seeking rapid market entry. Supply risk centers on single-source enzymes and membranes, while reimbursement coding decisions determine downstream pricing ceilings. High switching costs arise from closed-system consumables and LIS integration requirements; regional divergence in WHO versus CDC testing algorithms forces kit vendors to maintain parallel product configurations.

Recent Industry Insights

The Herpes Simplex Virus Testing Kits industry trends have accelerated since late 2022, driven by a surge in at-home diagnostics and multiplex technologies. In March 2023, Cepheid acquired Luminex’s molecular virology assets, integrating HSV-1/2 assays into the GeneXpert platform to deliver results in <15 minutes and strengthening near-patient testing in OB/GYN clinics. Everly Health and LetsGetChecked both launched HSV-2 antibody self-collection kits within Q2’23, leveraging smartphone-linked AI result interpretation and prompting a 38% YoY uptick in direct-to-consumer sales for sexual-health panels.

Regulatory momentum followed: the FDA’s reclassification of nucleic acid-based vaginal swabs to Class II (June 2023) shortened 510(k) review to 90 days, encouraging start-ups to enter the market. Meanwhile, EU IVDR 2022 compliance forced kit makers to add post-market surveillance data; firms that compiled real-world performance evidence—such as DiaSorin’s HERPE-select—secured CE-IVDR certification ahead of peers, capturing EU market share.

New funding underscores confidence: Curative closed a $45M Series C in Oct 2023 to scale kiosks bundling HSV with PrEP management, while Visby Health secured $23M to miniaturize its palm-sized PCR device, aiming for OTC clearance by 2025. These moves signal a decisive shift toward discreet, rapid, and highly integrated testing ecosystems, reshaping competitive dynamics in the Herpes Simplex Virus Testing Kits space.

Analyst Overview

The Herpes Simplex Virus Testing Kits market outlook signals a moderately attractive arena where rising HSV-2 incidence and self-testing adoption push a 6 % CAGR through 2030. Competitive intensity is high; multiplex panels and CLIA-waived POC claims crowd the space, compressing price points 3–4 % annually. Long-term value will accrue to firms embedding AI-guided result interpretation and fully integrated digital reporting, shifting revenues from kits to recurring software. Innovation is migrating toward isothermal amplification on disposable chips that deliver <15-minute results at <$5 COGS; patent cliffs on LAMP chemistry open windows for generics. Demand outstrips supply for high-throughput lyophilized bead formats, yet commodity swab-based SKUs face oversupply; expect selective capacity rationalization in 2025–26. Key risks stem from regulatory harmonization delays across IVD-R and FDA, potential molecular target drift in immunocompromised cohorts, and pricing erosion if public health systems consolidate tenders.

11 items

1. Executive Summary

2. Herpes Simplex Virus Testing Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Herpes Simplex Virus Testing Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Herpes Simplex Virus Testing Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Diagnostic Centers

6.1.2. Hospitals

6.1.3. Home Use

6.2. Global Herpes Simplex Virus Testing Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antibody/Antigen Based Kit

6.2.2. Viral Culture Test Kits

6.2.3. Nucleic Acid Amplification-based Kits

6.3. Global Herpes Simplex Virus Testing Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Herpes Simplex Virus Testing Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Herpes Simplex Virus Testing Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Herpes Simplex Virus Testing Kits Market Competition by Key Manufacturers

8.1. Global Herpes Simplex Virus Testing Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Herpes Simplex Virus Testing Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ADI/American Diagnostica

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Chrono-Log

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Corgenix

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Decode Genetics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Diadexus

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Diagnocure

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Diagnostica Stago/Trinity Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Diamedix

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. International Technidyne/Nexus DX

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Kreatech/Leica

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Polymedco

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Qiagen

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Roche

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. SDIX

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sequenom

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Siemens

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Herpes Simplex Virus Testing Kits Market

Figure 4: Global Herpes Simplex Virus Testing Kits Market: Drivers

Figure 5: Global Herpes Simplex Virus Testing Kits Market: Challenges

Figure 6: Global Herpes Simplex Virus Testing Kits Market: Trends

Figure 7: Global Herpes Simplex Virus Testing Kits Market: Opportunity

Figure 8: Global Herpes Simplex Virus Testing Kits Market: Restraint

Figure 9: Global Herpes Simplex Virus Testing Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Herpes Simplex Virus Testing Kits Market Value (USD Million) By Region

Figure 15: Global Herpes Simplex Virus Testing Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Herpes Simplex Virus Testing Kits Market Value (USD Million) By Region

Figure 23: Global Herpes Simplex Virus Testing Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Herpes Simplex Virus Testing Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Herpes Simplex Virus Testing Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Herpes Simplex Virus Testing Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Herpes Simplex Virus Testing Kits Market Value (USD Million) By Region

Table 10: Global Herpes Simplex Virus Testing Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Herpes Simplex Virus Testing Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Herpes Simplex Virus Testing Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Herpes Simplex Virus Testing Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: ADI/American Diagnostica Basic Information And Sales Area

Table 33: ADI/American Diagnostica. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: Chrono-Log Basic Information And Sales Area

Table 37: Chrono-Log. Products Portfolio

Table 38: Corgenix Basic Information And Sales Area

Table 39: Corgenix. Products Portfolio

Table 40: Decode Genetics Basic Information And Sales Area

Table 41: Decode Genetics. Products Portfolio

Table 42: Diadexus Basic Information And Sales Area

Table 43: Diadexus. Products Portfolio

Table 44: Diagnocure Basic Information And Sales Area

Table 45: Diagnocure. Products Portfolio

Table 46: Diagnostica Stago/Trinity Biotech Basic Information And Sales Area

Table 47: Diagnostica Stago/Trinity Biotech. Products Portfolio

Table 48: Diamedix Basic Information And Sales Area

Table 49: Diamedix. Products Portfolio

Table 50: International Technidyne/Nexus DX Basic Information And Sales Area

Table 51: International Technidyne/Nexus DX. Products Portfolio

Table 52: Kreatech/Leica Basic Information And Sales Area

Table 53: Kreatech/Leica. Products Portfolio

Table 54: Polymedco Basic Information And Sales Area

Table 55: Polymedco. Products Portfolio

Table 56: Qiagen Basic Information And Sales Area

Table 57: Qiagen. Products Portfolio

Table 58: Roche Basic Information And Sales Area

Table 59: Roche. Products Portfolio

Table 60: SDIX Basic Information And Sales Area

Table 61: SDIX. Products Portfolio

Table 62: Sequenom Basic Information And Sales Area

Table 63: Sequenom. Products Portfolio

Table 64: Siemens Basic Information And Sales Area

Table 65: Siemens. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Herpes Simplex Virus Testing Kits Market Value (USD Million) By Region

Table 71: Global Herpes Simplex Virus Testing Kits Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current size of the Herpes Simpleus Virus Testing Kits market?

Herpes Simplex Virus Testing Kits market size was valued at USD 1.2 billion in 2023, supported by increasing awareness and diagnostic demand.

2. What is the expected growth rate for the future outlook of the Herpesus Simplex Virus Testing Kits market?

The future outlook of the Herpesus Simplex Virus Testing Kits market predicts a 6.5% CAGR through 2030, fuelled by rapid point-of-care testing adoption.

3. What are the key drivers of market growth?

Key drivers include rising HSV infection rates, technological shifts toward molecular assays, and heightened focus on preventive sexual health procedures.

4. What challenges might slow the growth of the Herpesus Simplex Virus Testing Kits market?

Challenges include high costs, social stigma, reimbursement gaps, and limited diagnostic accuracy of rapid tests in resource-limited settings of the market.

5. Which regions are the largest markets for Herpesus Simplex Virus Testing Kits?

North America leads the Herpesus Simplex Virus Testing Kits market size, followed by Europe and Asia-Pacific, driven by advanced healthcare and awareness campaigns.

6.

Top companies include Abbott, Roche, Thermo Fisher, Bio-Rad, and DiaSorin, focusing on molecular platforms that enhance sensitivity and speed for market presence.

7. What future opportunities could accelerate the growth of the Herpesus Simpleus Virus Testing Kits market?

Future opportunities include self-testing home kits, multiplex panels for sexual health, AI-assisted diagnostics, and expansion into emerging markets via affordable pricing.

8. How is technology impact shaping the Herpesus Simplex Virus Testing Kits market?

Technology impact from real-time PCR, portable PCR, and smartphone-linked readers enhances accuracy and decentralization, driving the future outlook of the market.

9. What is the regulatory landscape for Herpesus Simplex Virus Testing Kits?

The regulatory landscape is stringent, with FDA and CE-IVD clearances for performance validation and safety, influencing market entry and pricing strategies.

Contact for Full Report

Loading report content...

Herpes Simplex Virus Testing Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; ADI/American Diagnostica; Agilent Technologies; Chrono-Log; Corgenix; Decode Genetics; Diadexus; Diagnocure; Diagnostica Stago/Trinity Biotech; Diamedix; International Technidyne/Nexus DX; Kreatech/Leica; Polymedco; Qiagen; Roche; SDIX; Sequenom; Siemens
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Regional Insights

Loading chart…

Competitive Landscape

Abbott: platform integration and menu densification drive pull-through

Qiagen: OEM supply alliances and open-system PCR consumables

Roche: premium pricing anchored by integrated sample-to-result workflows

Siemens: regional expansion via distributor partnerships in LATAM and APAC

Corgenix: local manufacturing to cut lead times and landed cost

Diadexus: focused R&D pipeline for multiplex HSV/VZV assays

Key Herpes Simplex Virus Testing Kits Companies18 items

Abbott

ADI/American Diagnostica

Agilent Technologies

Chrono-Log

Corgenix

Decode Genetics

Diadexus

Diagnocure

Diagnostica Stago/Trinity Biotech

Diamedix

International Technidyne/Nexus DX

Kreatech/Leica

Polymedco

Qiagen

Roche

SDIX

Sequenom

Siemens

Market Ecosystem

Raw material suppliers — produce primers, probes, antigens, and nitrocellulose membranes under ISO 13485 traceability.

Assay developers — integrate reagents into PCR, isothermal, or lateral-flow formats and generate analytical validation data.

Platform technology providers — supply thermal cyclers, fluorescence detectors, and benchtop readers with embedded software.

Contract manufacturers — perform bulk lyophilization, blister packaging, and kit assembly under GMP controls.

Regulatory consultants — prepare 510(k) or CE-IVDR dossiers and manage post-market surveillance documentation.

Distributors — stock temperature-controlled inventory, offer local language support, and handle customs clearance.

End users — hospital labs, sexual-health clinics, and retail pharmacies that process specimens and report results.

Recent Industry Insights

Analyst Overview

Table of Contents